Clinical analysis of Paclitaxel and Platinum in Recurrent Carcinoma of the Uterine Cervix.
- Author:
Seung Wook JEON
1
;
Young Tak JU
;
Ji Hyeon KIM
;
Ok Joo AHN
;
Young MOON
;
Kwang Beom LEE
;
Jin Woo SHIN
;
Jong Min LEE
;
Chan Yong PARK
Author Information
1. Department of Obstetrics and Gynecology, Gachon Medical School, Inchon, Korea. mjb307@hanmail.net
- Publication Type:Original Article
- Keywords:
Recurrent;
Cervical cancer;
Paclitaxel;
Platinum
- MeSH:
Agranulocytosis;
Area Under Curve;
Carboplatin;
Cervix Uteri*;
Cisplatin;
Drug Therapy;
Drug Therapy, Combination;
Female;
Humans;
Paclitaxel*;
Platinum*;
Sepsis;
Uterine Cervical Neoplasms
- From:Korean Journal of Obstetrics and Gynecology
2005;48(6):1448-1455
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: This study was performed to evaluate the efficacy and the toxicity of paclitaxel and platinum in patients with recurrent cervical carcinoma. METHODS: Twenty nine patients were treated with paclitaxel 135-175 mg/m2 and cisplatin 50-75 mg/m2 or carboplatin at AUC 5 every 3 weeks for a maximum of six courses from January 2001 to January 2004. RESULTS: A total 134 cycles with paclitaxel and platinum were administered. Ten patients (34.2%) achieved an objective response, including four complete responses (13.6%) and six partial responses (20.6%). Overall survival was 13.2 months, and the response and non-response group were 23.2 and 8.1 months, respectively (p=0.01). Clinical response according to recurrent site was significantly different (p=0.048) but, survival was not (p=0.22). Grade 3 or 4 granulocytopenia in 75.9% of patients was developed and one expired due to neutropenic sepsis after first cycle chemotherapy. CONCLUSION: The combination of paclitaxel and platinum seems relatively well tolerated and has 34.2% response rate in patients with recurrent cervical cancer. Further study for this combination chemotherapy and prognostic factor should be needed.
